BioVector® TB096 (TB096-2) 人源 IDH1 突变型星形细胞瘤细胞系

BioVector® TB096 (TB096-2) Human IDH1-Mutated Astrocytoma Cell Line Manual

第一部分 中文说明

一 产品基本信息与遗传学背景

• 细胞名称：TB096（常写作 TB096-2 或 TB096-0096）人源 IDH1 突变型星形细胞瘤细胞系

• 物种来源：人源（Human），衍生自一名 26 岁男性间变性星形细胞瘤（Anaplastic Astrocytoma, WHO Grade III）患者。由杜克大学（Duke University）脑肿瘤生物样本库通过患者知情同意建立。

• 核心遗传学与分子标志：

  • IDH1 R132H 杂合突变（经典肿瘤标志）：本细胞系基因组在 IDH1（NADP+ 依赖性异柠檬酸脱氢酶 1）编码区的 Arg132 (R132) 位置存在特异性单点突变（常见为杂合子，即一个等位基因为野生型，另一个基因为突变型，变为组氨酸 His/H）。

  • 致癌代谢产物 D-2HG 高分泌（Gain-of-Function）：野生型 IDH1 催化异柠檬酸转化为 $\alpha$-酮戊二酸（$\alpha$-KG），而突变型的 IDH1 酶获得了全新的功能（Gain-of-function），会逆向将 $\alpha$-KG 进一步还原为“癌性代谢物”——D-2-羟基戊二酸（D-2-hydroxyglutarate, D-2HG）。该细胞系在体外培养时能够持续稳定地高丰度分泌 D-2HG。

  • 伴随突变（TP53 突变）：该细胞系同时携带纯合的 TP53 基因 245 位点突变（甘氨酸 Gly 突变为缬氨酸 Val），完美模拟了临床上 IDH 突变型神经胶质瘤常伴随 p53 通路失活的真实分子病理图谱。

• 生长特性：贴壁生长（Adherent growth），主要呈现典型的神经胶质/星形细胞多角形或纺锤形形态。

• 生物安全级别：1级或2级潜力（BSL-1 / BSL-2 视各实验室人类来源样本规范而定）。菌株/细胞已通过 Charles River 的人类基本传染病筛查（CLEAR panel），证实无支原体、无小鼠/大鼠/非人灵长类等外源交叉污染。

二 核心科研价值与转化医学应用

传统上，含有天然 IDH1 突变的原代胶质瘤细胞极其难以在体外长期传代，突变位点极易在人工培养中丢失。TB096 是目前国际公认的、极少数能长久稳定维持 IDH1 R132H 突变表型的标准化体外细胞模型：

1. 致癌肿瘤代谢学（Oncometabolism）研究：用于深入探究 D-2HG 在胞内积累后如何引发全面性的 DNA 恶性超甲基化（Hypermethylation）以及组蛋白修饰改变，进而阻断星形胶质细胞的正常分化并驱动癌变的精细机制。

2. 靶向药物研发与耐药性监控（Drug Screening）：是筛选新型突变型 IDH1 小分子抑制剂（如 Vorasidenib、Ivosidenib）以及评估靶向药物在克服血脑屏障（BBB）后体外杀伤动力学的首选阳性细胞模型，常用于研究 PHGDH 或其他代谢通路引发的获得性耐药。

3. 同源异形控制模型（Isogenic Tumor Modeling）：可利用 CRISPR/Cas9 或 AAV 基因靶向技术敲除其突变或野生型等位基因，构建完美的同源细胞控制矩阵。

三 实验室细胞复苏、扩增传代与冷冻保存标准步骤

1. 专用培养基配置（Expansion Medium）

TB096 属于神经外胚层来源的高级恶性肿瘤细胞，对血清质量和基质渗透压有特定要求：

• 基础配置方案（混合培养基，推荐）：

  • 50% NBE 培养基 + 50% DMEM 高糖培养基

  • 补充添加：10% 优质胎牛血清（FBS） + 1% 灭菌双抗（Penicillin-Streptomycin）。

• 注：若用于维持其干细胞/神经球样分化潜能，部分实验室会使用不含血清的神经干细胞增殖培养基（补充 20 ng/mL EGF 和 10 ng/mL bFGF），但贴壁常规扩增首选上述含血清配方。

2. 细胞复苏（Thawing Protocol）

1. 从液氮罐中取出 TB096 冻存管，立即投入 37 摄氏度恒温水浴箱中，轻微晃动。

2. 在 1 到 2 分钟内令其急速完全融化（至仅剩极小冰芯）。注：复苏过程必须极为迅速，避免二甲基亚砜（DMSO）在室温融化状态下对细胞产生强烈的细胞毒性。

3. 消毒冻存管外部，移入生物安全柜。用移液管将细胞悬液吸出，置于 15 mL 干净离心管中。

4. 极重要（防止渗透压休克）：用移液管吸取 9 mL 预热的 TB096 专用扩增培养基，以滴加的方式（Dropwise）极其缓慢地加入到离心管中，期间轻轻转动离心管。严禁一次性快速倾倒全部培养基！

5. 300 × g 离心 2 至 3 分钟，轻轻倒掉含有 DMSO 的上清液。

6. 加入 2-5 mL 新鲜培养基，用移液枪极轻柔地吹打 2 次以重悬细胞，严禁剧烈震荡（Vortex）。随后接种于培养瓶中，置于 37°C、5% $CO_2$ 孵箱中培养。

3. 细胞传代（Passaging / Subculture）

• 传代时机：切勿让细胞长至 100% 完全融合。当细胞密度达到约 70% - 80% 融合度时必须执行传代。

• 传代步骤：

  1. 吸除旧培养基，使用无菌 PBS 轻轻洗涤细胞表面 1-2 次。

  2. 加入适量 Accutase™（阿库酶/广谱细胞消化液）（一般 T25 瓶加 2-3 mL，T75 瓶加 5-7 mL），确保覆盖细胞。

  3. 置于 37°C 孵箱中消化 3 至 5 分钟。在显微镜下观察，当绝大部分细胞变圆且开始脱离瓶壁时，轻轻拍打瓶身使其完全脱落。

  4. 加入 2 倍体积的常规扩增培养基终止消化，收集至离心管中。

  5. 计数后，按照常规 1:4 至 1:6 的比例（根据细胞活力及实验周期调整）传代接种到新的培养皿/瓶中。

4. 细胞冷冻保存（Cryopreservation）

• 冻存液配方：90% 优质胎牛血清（FBS）+ 10% 医用级 DMSO，或使用无血清无蛋白的高效细胞冻存液。

• 冻存操作：收集处于对数生长旺盛期（融合度约 75%）的细胞，离心弃上清。调整细胞密度至 $\ge 1 \times 10^6$ cells/vial。加入冻存液重悬后分装入冻存管，立即投入标准程序降温盒（异丙醇梯度降温盒，1°C/min），置于 -80°C 过夜，次日必须转移至 -196°C 液氮中进行无限期冷冻长期保存。

PART 2 ENGLISH SECTION

I General Information and Genetic Architecture

• Cell Line Name: TB096 (Also specified as TB096-2 or TB096-0096) Human IDH1-Mutated Astrocytoma Cell Line.

• Species Origin: Human.Derived from a 26-year-old male patient diagnosed with anaplastic astrocytoma (WHO Grade III) treated at Duke University in 2009.Tissues were harvested under full Institutional Review Board (IRB) compliance and patient written consent.

• Core Genetic and Molecular Signatures:

  • Heterozygous IDH1 R132H Mutation: Represents an invaluable, globally recognized stable in vitro platform harboring the definitive Arg132 to Histidine (R132H) single point mutation within the IDH1 (NADP+-dependent isocitrate dehydrogenase 1) locus.

  • Oncometabolite D-2HG Hyper-Secretion (Gain-of-Function): While wild-type IDH1 converts isocitrate to $\alpha$-ketoglutarate ($\alpha$-KG), the mutated IDH1 enzyme acquires an aggressive oncogenic gain-of-function metabolic profile.It sequentially reduces $\alpha$-KG into the prominent oncometabolite D-2-hydroxyglutarate (D-2HG). This cell line consistently manufactures and releases high baseline titers of D-2HG into culture supernatants.

  • Concomitant TP53 Disruption: Co-harbors a homozygous TP53 mutation at codon 245 (Gly to Val substitution), perfectly mirroring the actual clinical, co-occurring molecular pathology found in human IDH-mutant astrocytic lineages.

• Growth Topology: Adherent growth mode. Displays distinct polygonal, bipolar, or spindle-shaped astrocytic/glial morphologies.

• Biosafety Matrix: BSL-1 or BSL-2 depending on institutional biosafety guidelines for handling human-derived materials. Verified strictly negative for mycoplasma, viral pathogens, and interspecies cross-contaminations (tested negative via the Charles River Human Essential CLEAR panel).

II Strategic Research Value & Translational Fields

Primary glioma cells isolating endogenous IDH1 mutations historically suffer from an inability to propagate long-term in vitro, rapidly losing or counter-selecting the mutant allele across passages. TB096 stands out as a robust model that preserves the intact IDH1 R132H mutational phenotype across decades of subculturing:

1. Cancer Oncometabolism Exploration: Ideal for decoding downstream epigenetic reprogramming, specifically how chronic intracellular D-2HG pooling drives systemic CpG island methylator phenotypes (G-CIMP), inhibits $\alpha$-KG-dependent dioxygenases, blocks differentiation, and dictates gliomagenesis.

2. Targeted Therapeutics & Resistance Screens: Serves as a definitive positive control model for validating small-molecule mutant-IDH1 dual-inhibitors (e.g., Vorasidenib, Ivosidenib), mapping pharmacological parameters across the blood-brain barrier (BBB), and identifying alternate enzymatic escape loops (such as PHGDH-driven bypass resistance).

3. Isogenic Modification & Metrology: Provides a uniform target for CRISPR-Cas9 or AAV-mediated homologous editing to engineer clean wild-type/mutant paired control cell matrices.

III Thawing, Proliferation, Passaging, and Cryopreservation Routines

1. Formulating the Complete Expansion Medium

As neuroectodermal malignant cells, TB096 demands exact nutritional osmolarity balances:

• Standard Dual-Base Protocol (Highly Recommended):

  • 50% NBE (Neurobasal Medium Alternate) + 50% High-Glucose DMEM

  • Supplements: Fortified with 10% premium Fetal Bovine Serum (FBS) and 1% Penicillin-Streptomycin cocktail.

• Note: For highly specialized neurosphere lineage maintenance, some pipelines implement serum-free neural stem frameworks supplemented with 20 ng/mL EGF and 10 ng/mL bFGF; however, regular monolayer proliferation is optimally driven by the serum-fortified matrix above.

2. Cryovial Thawing Routine

1. Retrieve the TB096 cryovial from liquid nitrogen storage and instantly submerge it into a 37°C water bath with gentle agitation.

2. Complete the thawing cycle rapidly within 1 to 2 minutes (stop when a minuscule ice crystal remains). Note: Rapid thawing is mandatory to prevent prolonged ambient exposure to liquefied DMSO, which exercises acute chemical cytotoxicity.

3. Disinfect the vial exterior with 70% ethanol, transit into a biosafety cabinet, and siphon the cells into a sterile 15 mL conical tube.

4. CRITICAL STEP (Osmotic Shock Countermeasure): Utilizing a serological pipette, draw 9 mL of pre-warmed complete Expansion Medium. Slowly add the medium dropwise to the cell pellet while gently swirling the tube. Never dump the entire volume of media all at once into the cells.

5. Centrifuge the suspension at 300 × g for 2 to 3 minutes, then decant the DMSO-polluted supernatant.

6. Replenish with 2–5 mL of fresh medium, and gently pipette up and down twice to resuspend the cells. Do not vortex. Plate the cell slurry into standard culture flasks and incubate at 37°C under 5% $CO_2$.

3. Subculturing and Cell Passaging Guide

• Confluency Threshold: Do not allow the cultures to grow to 100% confluency. Execute passaging promptly when the monolayer strikes 70%–80% confluency.

• Step-by-Step Harvesting:

  1. Aspirate the spent culture medium and gently wash the adherent layers 1–2 times with sterile PBS.

  2. Disperse an optimal volume of Accutase™ Dissociation Solution across the matrix (approx. 2–3 mL for T25 flasks; 5–7 mL for T75 flasks).

  3. Incubate at 37°C for 3 to 5 minutes. Monitor under an inverted microscope; as soon as the cells round up and start detaching, gently tap the flask to dislodge the remaining layer.

  4. Quench the enzyme immediately by introducing a double volume of serum-containing complete Expansion Medium, then transfer the slurry into a conical tube.

  5. Perform a cell count via hemocytometer and re-plate into fresh flasks at a standard split ratio of 1:4 to 1:6.

4. Cryopreservation Protocol

• Freezing Medium Matrix: 90% Premium FBS + 10% Tissue-Culture Grade DMSO, or validated protein-free commercial cryopreservation solutions.

• Freezing Routine: Harvest cells harvesting during their active log-growth phase (~75% confluent). Spin down, discard supernatant, and adjust the cell density to $\ge 1 \times 10^6$ viable cells/vial. Aliquot into cryovials and place inside a standardized isopropyl alcohol freezing container (giving a cooling rate of -1°C/minute). Stash at -80°C overnight, and transfer into liquid nitrogen (-196°C) the following day for indefinite preservation.

BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

电话:400-800-2947

工作QQ/微信同号:1843439339

网址http://www.biovector.net